A biologically active peptide homologous to a yeast fermentation product and its application

Abstract

The present invention relates to the fields of biomedicine and daily chemicals, and discloses a bioactive peptide having an amino acid sequence of ETRIL, or derivatives thereof having the same biological activity obtained by hydroxylating, carboxylating, carbonylating, methylating, acetylating, phosphorylating, esterifying, or glycosylating the amino acid side chain groups, the amino terminus, or the carboxyl terminus. The bioactive peptide has excellent anti-aging, antioxidant, and sunscreen skin care benefits, is homologous to yeast fermentation products, and can be used in pharmaceuticals, health products, foods, daily chemicals, and other fields, showing promising application prospects.

Description

Technical Field

[0001] The present application relates to the fields of biomedicine and daily chemicals, and specifically to the application of a bioactive peptide with anti-aging activity, as well as a skin care product or medicine with the bioactive peptide as the main ingredient. Background Art

[0002] Bioactive peptides are a class of polypeptides that are beneficial to the health of the body or have certain specific biological functions. They are specific protein fragments composed of short amino acid sequences. They are generally composed of 2 or more than 20 amino acids and less than 20 amino acids polymerized through peptide bonds, with a molecular weight of less than 6kDa. Due to their special biological activity, they have become a basic component of protein structure and function. They can be obtained from protein hydrolysates through enzymatic hydrolysis, microbial fermentation, acid and alkali treatment, etc. Bioactive peptides have a wide range of biological activities, including antioxidant, ACE inhibition, anti-tumor, immunomodulatory, anti-aging and anti-inflammatory. Due to their high specificity, low toxicity, high structural diversity and low molecular weight, bioactive peptides are widely used in the pharmaceutical, food, cosmetics and other industries.

[0003] Skin aging is an outward manifestation of human aging. Studies have shown that the main cause of skin aging is that oxygen free radicals produced by factors such as ultraviolet rays affect the normal growth cycle of the skin, prompting the hydrolysis of extracellular matrices such as collagen by proteases, and causing DNA damage, resulting in reduced matrix protein synthesis, ultimately leading to sagging skin and reduced elasticity. Since the 1990s, researchers have been preventing and modifying the physiological structure of the skin or exogenous factors that cause skin aging by adding biomacromolecules such as DNA and proteins. However, these large molecular active ingredients are difficult to be absorbed through the epidermis. Current research shows that small molecule bioactive peptides have the characteristics of good safety and high biological activity, and are more likely to penetrate the skin barrier. Peptides with anti-aging activity can control or regulate the skin aging process, thereby protecting skin damage and delaying skin aging.

[0004] A fermentation product of the Himalayan yeast Saccharomyces cerevisiae (CN114081862A, China General Microbial Culture Collection No. CGMCC No. 19732), it contains a variety of skin-beneficial ingredients, including proteins, peptides, amino acids, minerals, and vitamins. It exhibits excellent repair and cell regeneration properties, promoting skin cell proliferation and collagen regeneration, thereby achieving anti-aging and repair effects. By studying the proteins and peptides identified in Ximoyin samples, if bioactive peptides with skincare benefits can be identified, particularly short peptides with smaller molecular weights, they will be crucial for promoting skin absorption and enhancing the product's anti-aging activity or other skincare benefits. Summary of the Invention

[0005] Based on the deficiencies of the prior art, the present invention provides a bioactive peptide with anti-aging efficacy and its application.

[0006] In a first aspect, the present invention relates to a bioactive peptide EL-5, whose amino acid sequence is ETRIL, as shown in SEQ ID No. 1.

[0007] The bioactive peptide EL-5 is homologous to hyaluronic acid. It is a short peptide obtained from the fermentation product of Saccharomyces cerevisiae strain (CGMCC No. 19732) through experiments and bioinformatics analysis. Its molecular weight is about 700 Da, and it has excellent anti-aging, antioxidant, sun protection and other skin care effects.

[0008] In some embodiments, modifications such as hydroxylation, carboxylation, carbonylation, methylation, acetylation, phosphorylation, esterification or glycosylation can be performed on the amino acid side chain groups, amino terminus or carboxyl terminus of the bioactive peptide to obtain derivatives of the bioactive peptide without affecting its biological activity.

[0009] The bioactive peptide EL-5 can promote the production of collagen, especially after damage caused by ultraviolet radiation, and significantly increase the content of type I collagen.

[0010] The bioactive peptide EL-5 can increase the expression and content of Ki67 and ATP levels, promoting cell proliferation and skin repair. This is particularly true after UVA or hydrogen peroxide induction, where it increases Ki67 expression and promotes cell proliferation. Therefore, it has anti-aging, sun protection, and anti-photoaging effects.

[0011] The bioactive peptide EL-5 also has antioxidant effects, inhibiting hydroxyl free radicals and oxygen free radicals, especially reducing the content of ROS after hydrogen peroxide induction.

[0012] The bioactive peptide EL-5 can also reduce inflammatory responses, specifically UV-induced inflammatory responses, especially inhibiting the release of UVB-induced IL-8 inflammatory factors.

[0013] In some embodiments, the N-terminus of the bioactive peptide is acetylated and the C-terminus is amidated.

[0014] In a second aspect, the present invention relates to a pharmaceutical composition comprising the bioactive peptide EL-5, and further comprising a pharmaceutically acceptable carrier and / or a fermentation product of Saccharomyces cerevisiae with a deposit number of CGMCC No. 19732.

[0015] In some embodiments, the fermentation product is selected from any one of fermentation broth, fermentation filtrate, concentrated solution of fermentation broth or fermentation filtrate, dry powder of fermentation broth or fermentation filtrate, or any combination thereof.

[0016] In some embodiments, the pharmaceutically acceptable carrier is selected from any one of isotonic saline, ethanol, phosphate-buffered saline, sorbitol, mannitol, starch, acacia gum, gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, or any combination thereof.

[0017] In other embodiments, the composition can be administered orally, buccally, by application, by inhalation, rectally, nasally, ophthalmically, or parenterally.

[0018] In other embodiments, the dosage form of the composition includes any one of an oral dosage form, a parenteral dosage form, a buccal dosage form, a sublingual dosage form, a nasal dosage form, an inhaler, a spray, a topical dosage form, a transdermal dosage form, a suppository, or any combination thereof.

[0019] In a third aspect, the present invention relates to a daily chemical composition comprising the above-mentioned bioactive peptide EL-5.

[0020] In some embodiments, the daily chemical composition further contains a fermentation product of Saccharomyces cerevisiae with a preservation number of CGMCC No. 19732. The fermentation product is selected from any one of fermentation broth, fermentation filtrate, concentrated solution of fermentation broth or fermentation filtrate, dry powder of fermentation broth or fermentation filtrate, or any combination thereof.

[0021] In a fourth aspect, the present invention relates to the use of the above-mentioned bioactive peptides or daily chemical compositions for preparing health products or foods.

[0022] In some embodiments, the bioactive peptides or daily chemical compositions can reduce collagen degradation and smooth fine lines; accelerate skin cell growth and inhibit oxygen free radicals and hydroxyl free radicals; and as a strong antioxidant, can inhibit photoaging; can also repair damaged skin, rebuild epidermal structure, and tighten the skin; reduce inflammatory responses and provide long-lasting soothing effects.

[0023] In other embodiments, the bioactive peptide or daily chemical composition can increase the content of type I collagen, increase the expression of ki67, and increase the ATP content; inhibit ROS generation, and antagonize IL-8 inflammatory factors, especially UVB-induced IL-8 inflammatory factors.

[0024] The bioactive peptide EL-5 and the fermentation product of Saccharomyces cerevisiae with the deposit number of CGMCC No.19732 (himoin) can produce synergistic synergy.

[0025] The composition of EL-5 and the fermentation product of Hirmyn yeast has a synergistic effect in increasing the content of ColI (type I collagen), especially being able to significantly increase the content of type I collagen after ultraviolet irradiation.

[0026] In a fifth aspect, the present invention relates to the bioactive peptide or the pharmaceutical composition or daily chemical composition being used to prepare skin care products or cosmetics, especially skin care products with anti-aging and sun protection effects.

[0027] In some embodiments, the cosmetic or skin care product has anti-aging benefits.

[0028] In some embodiments, the cosmetics or skin care products have antioxidant, sun protection, and anti-photoaging effects.

[0029] In some embodiments, the cosmetic or skin care product has an antioxidant effect, inhibiting hydroxyl and oxygen free radicals, particularly ROS induced by hydrogen peroxide. It can also increase Ki67 expression and ATP levels, promoting skin cell proliferation. It can also increase type I collagen levels, promoting its production and secretion, particularly after UV damage. Furthermore, it can reduce inflammatory responses, inhibiting UVB-induced IL-8 inflammatory cytokine release.

[0030] In a sixth aspect, the present invention relates to a method for preparing the bioactive peptide, which is prepared by genetic engineering, enzyme engineering or chemical synthesis.

[0031] The present invention provides a bioactive peptide that promotes collagen secretion and cell proliferation, and exhibits anti-inflammatory and antioxidant effects, demonstrating excellent anti-aging, antioxidant, and photoaging benefits. This active peptide, derived from the protein profile of a hyaluronic acid sample, is homologous to yeast fermentation products. Compared to existing technologies, this bioactive peptide is shorter and has a lower molecular weight, reducing production costs while increasing activity. It also facilitates absorption and has promising applications in pharmaceuticals, health supplements, foods, and daily chemical products. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 These are the results of biological activity tests on EL-5 and EL-6 in promoting the secretion of type I collagen by HFF-1 cells after ultraviolet irradiation.

[0033] Figure 2 These are the results of a biological activity test on EL-5 and hyaluronic acid promoting the secretion of type I collagen by HFF-1 cells after ultraviolet irradiation.

[0034] Figure 3 The results of the test experiment show that EL-5 promotes the expression of Ki67 in HFF-1 cells.

[0035] Figure 4 The results of the test experiment show that EL-5 promotes the expression of Ki67 in HaCaT cells.

[0036] Figure 5 These are the experimental results of EL-5 inhibiting ROS in FB cells.

[0037] Figure 6 The test results of EL-5 to increase the ATP content of fibroblasts.

[0038] Figure 7 The results of the test of EL-5 antagonizing UVB-induced IL-8. DETAILED DESCRIPTION

[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as understood by those of ordinary skill in the art. For definitions and terminology in this field, professionals are specifically referred to Current Protocols in Molecular Biology (Ausubel). The abbreviations for amino acid residues are the standard three-letter and / or one-letter codes used in the art to designate one of the 20 commonly used L-amino acids.

[0040] Although the numerical ranges and parameter approximations shown in the broad scope of this application, the numerical values ​​shown in the specific examples are recorded as accurately as possible. However, any numerical value is necessarily contained in a certain error, which is caused by the standard deviation present in their respective measurements. In addition, all ranges disclosed herein should be understood to cover any and all sub-ranges contained therein. For example, a range of "1 to 10" should be considered to include any and all sub-ranges between a minimum of 1 and a maximum of 10 (including endpoints); that is, all sub-ranges starting with a minimum of 1 or greater, such as 1 to 6.1, and sub-ranges ending with a maximum of 10 or less, such as 5.5 to 10. In addition, any reference referred to as "incorporated herein" should be understood to be incorporated in its entirety.

[0041] Example 1 Acquisition of EL-5 short peptide

[0042] CN114081862A discloses a brewer's yeast derived from highland barley wine koji with a deposit number of CGMCC No. 19732. Its fermentation product (himoin) has the ability to scavenge free radicals, promote cell proliferation, inhibit tyrosinase, protect skin cells from damage caused by oxidation or ultraviolet rays, and regulate skin flora and microecology, thereby achieving antioxidant, anti-aging, sun protection, improving skin cell vitality and protecting the skin barrier.

[0043] After ingredient analysis, it was found that it contains a variety of active ingredients such as organic acids, phenolic vitamins, free amino acids, peptides and protein components.

[0044] Further mass spectrometry analysis of the protein components in the fermentation product revealed a variety of candidate protein polypeptide molecules, one of which had an amino acid sequence of ETRIL (abbreviated as EL-5) with a molecular weight of approximately 700 Da.

[0045] EL-5 can be produced through genetic engineering, enzyme engineering, or chemical synthesis. The following tests examine the various effects of EL-5.

[0046] Example 2 Col I test experiment

[0047] EL-5 and its analogue EL-6 (amino acid sequence: ETRILL, SEQ ID No. 2) were used to detect their effects on promoting the production of type I collagen (ColI) in human fibroblasts (HFF-1) after ultraviolet irradiation, with TGF-β1 as a positive control.

[0048] (1) Plating: HFF-1 cells were digested and resuspended, and the cell number was counted using a Counstar cell technology instrument. Finally, DMEM complete medium (WISENT, 319-010-CL) containing cells was added to a 24-well plate. The final cell density was 8×10 4 After plating, place the cells in a cell culture incubator for 24 hours;

[0049] (2) Induction and sample addition: When the cell culture confluence reaches about 40% to 60%, the drug is administered. 1 mL of DMEM complete medium is added to each well of the blank control group and the model group; 1 mL of DMEM complete medium containing 100 ng / mL TGF-β1 is added to each well of the positive control group; and 1 mL of DMEM complete medium containing the test substance at the corresponding concentration (10 ppm, 25 ppm) is added to each well of the sample group.

[0050] (3) UV induction: 24 h after administration, the model group, positive control group, and sample group (EL-6 / EL-5: 10 ppm and 25 ppm) received a total dose of 8 mJ / cm for 10 min 25 s. 2 UVA radiation, while the blank control group was placed in the same environment (UVA radiation dose of 0J / cm 2 ).

[0051] (4) Sample collection: After 24 hours of incubation, collect the cell culture supernatant in an EP tube and store it in a freezer at -80°C. Add 0.5 mL of lysis buffer to each well and lyse the cells by pipetting. Collect the cell fluid in an EP tube and store the collected samples for testing in a freezer at -80°C. Detect the content of type I collagen using the detection kit.

[0052] like Figure 1The experimental results showed that compared with the blank control group, the ColI content in the induced model group was significantly reduced. Compared with the model group, the positive control group (TGF-β1 100ng / mL) showed a 354.88% increase. Compared with the model group, 10ppm EL-5 significantly increased the induced decrease in ColI content by 268.97%, while 25ppm EL-5 showed a 338.18% increase. Furthermore, compared with EL-6 at the same dosage, the shortened EL-5 significantly enhanced its ability to increase ColI content, achieving unexpected technical results.

[0053] In step (2), DMEM complete medium containing 0.1 ppm EL-5, 1 ppm EL-5, 5% (wt) hyaluronidase (fermentation broth), and 0.1 ppm EL-5 + 5% (wt) hyaluronidase (fermentation broth, prepared according to the method of CN114081862A) was added to the sample groups, respectively. After incubation, UV induction was performed according to the methods of steps (3) and (4), and samples were collected to detect their relative fluorescence intensity (Relative fluoresence intensity).

[0054] like Figure 2 Experimental results showed that compared to the blank control group, the ColI content in the model group after induction was significantly reduced. Compared to the model group, the positive control group (TGFβ1 100ng / mL) achieved a 329% increase. Compared to the model group, 0.1ppm EL-5 significantly increased ColI content by 125%, and 1ppm EL-5 significantly increased ColI content by 300%, exceeding the effect of 5% Himin yeast fermentation products. Furthermore, the combination of EL-5 and Himin yeast fermentation products exhibited a synergistic effect in increasing ColI content.

[0055] Biological experimental results show that EL-5 has a stronger ability to promote the secretion of type I collagen in HFF-1 cells after UVA damage than its analogue EL-6 (sequence: ETRILL). It has been confirmed that the effective peptide EL-5 matches 100% with a partial fragment of the protein identified in the Ximoyin sample, which has led to further research on the anti-aging and anti-photoaging activities of the Ximoyin effective peptide EL-5.

[0056] Example 3 HFF cell Ki67 test experiment

[0057] Ki67 is a protein related to cell proliferation. By detecting the Ki67 content in HFF-1 (human skin fibroblasts), it was found that EL-5 can increase the Ki67 content, especially after UVA induction.

[0058] Experimental materials: UVA-induced Ki67 content in HFF-1 cells (UVA induction dose: 40 mJ / cm 2 )

[0059] Experimental method: Cell culture and administration were similar to those in Example 2. 24 h after administration, the model group, positive control group, and sample group (EL-6 / EL-5: 10 ppm and 25 ppm) received a total dose of 40 mJ / cm for 30 min. 2 At the same time, the blank control group was placed in the same environment (UVA radiation dose of 0 J / cm 2 ).

[0060] Immunofluorescence was used to detect Ki67 expression. Specifically, cells were inoculated into a laser confocal microscope glass-bottom dish for immunofluorescence staining. After the cells were co-cultured for 24 or 48 hours to form a vascular network structure, the following cell fixation and staining steps were performed:

[0061] 1) Discard the culture medium and wash the cells three times with PBS;

[0062] 2) Add 4% paraformaldehyde and fix at room temperature for 15 minutes;

[0063] 3) Wash again with PBS three times, 5-10 minutes each time;

[0064] 4) Treat with 0.5% TritonX-100 for 3-5 minutes;

[0065] 5) Block with PBS containing 5% FBS for 1 hour;

[0066] 6) Dilute the primary antibody to 5-10 μg / ml in PBS containing 5% FBS and incubate overnight at 4°C.

[0067] 7) Wash with PBS three times, 5-10 minutes each time;

[0068] 8) Dilute the fluorescently labeled secondary antibody at 1:100 in PBS containing 5% FBS and incubate at room temperature in the dark for 2 hours;

[0069] 9) Wash once with PBS and stain with Hoechst 33342 or DAPI in PBS for 15 minutes in the dark;

[0070] Then, the sections were washed twice with PBS and then observed by fluorescence imaging or mounted with glycerol.

[0071] Test group: EL-5 (0.1ppm, 1ppm, 10ppm)

[0072] The results are as follows Figure 3The experimental results showed that compared with the blank control group (Control), UVA-induced Ki67 expression in HFF-1 cells was significantly reduced, and the model group (Model) experiment was successfully established. Compared with the model group, all three concentrations of EL-5 samples increased Ki67 expression (by 154.22%, 314.14%, and 453.16%, respectively) in a concentration-dependent manner. In summary, the EL-5 sample has a strong ability to enhance Ki67 expression after UVA induction, promoting skin cell proliferation and repair, especially after UVA irradiation, and thus has anti-photoaging effects.

[0073] Example 4 HaCaT cell ki67 test experiment

[0074] Experimental materials: Human immortalized keratinocytes (HaCaT cells) H2O2 induced ki67 test (induction intensity: 200μM, 6h), H2O2

[0075] Test group: EL-5 (0.1ppm, 1ppm, 10ppm)

[0076] Experimental Methods: Cell plating and culture were performed as in Example 3; Induction and sample addition: When the cell plating rate reached 40% to 60%, the cells were divided into groups and dosed. Three replicate wells were set up in each group, and 2 mL of liquid was added to each well. Culture medium was added to each well of the blank control group, culture medium containing 200 μM H₂O₂ was added to each well of the model group, and culture medium containing 0.1, 1, and 10 ppm of EL-5 sample and H₂O₂ was added to each well of the sample group. After 6 hours, the cells were placed in a CO₂ incubator (37°C, 5% CO₂) and cultured for an additional 24 hours.

[0077] The detection method is the same as in Example 3.

[0078] The experimental results are as follows Figure 4 As shown in the figure, compared with the blank control group (Control), H2O2-induced cells showed a significant decrease in Ki67 levels, demonstrating successful modeling. Compared with the model group, all three concentrations of EL-5 increased Ki67 levels (by 98.19%, 153.82%, and 251.29%, respectively), in a concentration-dependent manner. This suggests that EL-5 has the ability to increase Ki67 expression after H2O2 induction, making it a strong antioxidant with anti-aging effects.

[0079] Example 5 Fibroblast ROS test experiment

[0080] Experimental materials: fibroblasts FB; positive control VE, sample groups: 0, 1, 5 ppm EL-5.

[0081] Experimental methods:

[0082] (1) Plating: After thawed fibroblasts FB, when the plating rate reaches about 60%, the cells are seeded into 6-well plates and incubated overnight in a CO2 incubator (37°C, 5% CO2).

[0083] (2) Induction and sample addition: When the cell plating rate in the 6-well plate reaches 40% to 60%, the drug is administered in groups, with 3 replicate wells in each group and 2 mL of liquid added to each well. Culture medium is added to each well of the blank control (BC) group, culture medium containing 300 μM H2O2 is added to each well of the negative control (NC) group, culture medium containing 0.05% VE and 300 μM H2O2 is added to each well of the positive control (PC) group, and culture medium containing 0.1, 1, and 5 ppm of EL-5 sample and H2O2 is added to each well of the sample group. After completion, the 6-well plate is placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24 hours.

[0084] (3) ROS content detection: After the induction, the cells were directly washed 3 times with PBS, 1 mL of 10 μM DCFH-DA probe was added to each well, and the cells were incubated in a CO2 incubator (37°C, 5% CO2) for 30 min; the culture medium containing DCFH-DA was discarded, the cells were washed 3 times with PBS, and the cells were digested with trypsin (0.25%). The cells were washed once with PBS, a certain amount of fresh PBS was added, and flow cytometry was performed. The down-regulation rate was calculated according to the formula: down-regulation rate (%) = (negative control group - sample group) / negative control group × 100%.

[0085] The experimental results are as follows Figure 5 Compared with the blank control group BC, the ROS content in cells induced by H2O2 was significantly increased, indicating that the experimental model was successfully established (NC).

[0086] Compared to the negative control (NC), all three EL-5 concentrations significantly downregulated ROS levels (inhibition rates of 4.35%, 13.82%, and 23.22%, respectively) in a concentration-dependent manner. This indicates that under these experimental conditions, EL-5 has the ability to inhibit ROS levels in H2O2-induced fibroblasts, demonstrating its potential antioxidant properties.

[0087] Example 6 Fibroblast ATP content test experiment

[0088] Human primary dermal fibroblasts were expanded and cultured under 5% CO2 and 37°C. When the cells grew to 70-80% confluence, they were digested with trypsin and inoculated into 96-well plates for 48 hours. After 18 hours of starvation culture medium, the cells were divided into groups for drug administration. A blank control group (only culture medium added) and a sample group (culture medium containing 0.1, 1, and 5 ppm EL-5 samples) were set up. Each group had 3 parallel samples and cultured for 24 hours. After the experiment was completed, the cells were lysed and used Detect cellular ATP content using the reagent: Incubate at room temperature in the dark for 10 minutes, then read the results using a microplate reader (luminescence). Analyze the data using the ATP standard curve.

[0089] The experimental results are as follows Figure 6 As shown in the results, compared with the NT group, all three concentrations of EL-5 samples significantly increased the ATP content of fibroblasts (increased to 106.4%, 117.9%, and 116.1%, respectively). This shows that under the conditions of this experiment, the EL-5 sample has the ability to increase the ATP content in fibroblasts, which can promote cell proliferation and promote skin repair.

[0090] Example 7 HaCaT cell IL-8 test experiment

[0091] (1) Cell culture: Keratinocytes HaCaT were revived and, after the cell aggregation reached 80%, the cells were seeded into a 24-well plate and incubated overnight in a CO2 incubator (37°C, 5% CO2).

[0092] (2) UV induction: The culture medium in the well plate was removed and DPBS was added. The total dose received by the model group, positive control group and sample group was 11 mJ / cm 2 At the same time, the blank control group was placed in the same environment (UVB radiation dose of 0 J / cm 2 ).

[0093] (3) Induction and sample addition: After the induction is completed, remove the DPBS from the well plate. Add DMEM medium to each well of the blank control group and the model group, add DMEM medium containing 1 μg / mL dexamethasone to each well of the positive control group, and add DMEM medium containing 0.1, 1, and 5 ppm EL-5 samples to each well of the sample group. After completion, place the 24-well plate in a CO2 incubator (37°C, 5% CO2) and culture for 24 hours.

[0094] (4) Determination of IL-8 content: Collect the cell culture medium, centrifuge at 3000 rpm for 3 min, and collect the supernatant. Detect the IL-8 content according to the kit instructions. Use computer software to perform regression fitting to generate a standard curve, with the standard concentration as the horizontal axis and the OD value as the vertical axis. Determine the best fit curve by regression analysis. Calculate the corresponding IL-8 content in the test sample.

[0095] The experimental results are as follows Figure 7 Compared with the blank control group, the IL-8 content of HaCaT cells induced by UVB was significantly increased, indicating that the experimental model was successfully established.

[0096] Compared with the model group, all three concentrations of EL-5 (0.1, 1, and 5 ppm) significantly inhibited IL-8 secretion, reducing it by 17%, 23%, and 12%, respectively, with statistically significant differences between the groups. This suggests that EL-5 can effectively antagonize UVB-induced IL-8 inflammatory cytokine release, suggesting that it plays an important role in regulating the inflammatory pathway associated with skin photodamage.

[0097] The above describes the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included in the scope of protection of the present invention.

Claims

1. A bioactive peptide, characterized in that Its amino acid sequence is shown in SEQ ID No.

1.

2. A pharmaceutical composition, characterized in that Comprising the bioactive peptide according to claim 1.

3. The pharmaceutical composition according to claim 2, characterized in that The invention also contains a pharmaceutically acceptable carrier and / or a fermentation product of saccharomyces cerevisiae with a preservation number of CGMCC No.19732.

4. The pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable carrier is selected from any one or any combination of isotonic saline, ethanol, phosphate-buffered saline, sorbitol, mannitol, starch, gum, calcium phosphate, alginate, gelatin, calcium silicate, polyvinyl pyrrolidone, cellulose and water; and the fermentation product is selected from fermentation broth and / or fermentation filtrate.

5. The pharmaceutical composition according to any one of claims 2 to 4, wherein the dosage form comprises any one of an oral dosage form, a parenteral dosage form, a buccal dosage form, a spray, a topical dosage form and a transdermal dosage form, or any combination thereof.

6. A daily chemical composition, characterized in that Comprising the bioactive peptide according to claim 1.

7. The daily chemical composition according to claim 6, characterized in that The invention also contains a fermentation product of saccharomyces cerevisiae with a preservation number of CGMCC No.19732.

8. Use of the bioactive peptide according to claim 1 or the daily chemical composition according to any one of claims 6 to 7 in the preparation of health products or foods.

9. Use of the bioactive peptide according to claim 1, the pharmaceutical composition according to any one of claims 2 to 5, or the daily chemical composition according to any one of claims 6 to 7 in the preparation of skin care products or cosmetics with anti-aging, and / or sun protection, and / or anti-photoaging effects.

10. Use of the bioactive peptide according to claim 1, the pharmaceutical composition according to any one of claims 2 to 5, or the daily chemical composition according to any one of claims 6 to 7 in the preparation of skin care products or cosmetics having antioxidant effects, and / or skin cell proliferation promoting effects, and / or type I collagen increasing effects, and / or inflammatory response reducing effects.

11. A skin care product or cosmetic, characterized in that: Contains the bioactive peptide according to claim 1, the pharmaceutical composition according to any one of claims 2 to 5, or the daily chemical composition according to any one of claims 6 to 7.

Images